StreetInsider.com News Articles

Sernova and Seraxis close $11.2M financing ahead of merger

Mon, 05 Oct 2026 07:00:42 -0400

Sernova Biotherapeutics Inc. (TSX: SVA, OTC: SEOVF) and Seraxis Holdings, Inc. have closed a US$11.2 million non-brokered convertible note financing into Seraxis, according to a press release. The financing, which exceeded the initially targeted US$10 million, is connected to the companies' proposed merger to form BetaNova Biotherapeutics, Inc.

Participants in the financing include company insiders, management from both Sernova and Seraxis, existing shareholders, and new investors.

Proceeds are intended to fund several activities, including the cGMP manufacturing of SR-02, an allogeneic stem cell-derived pancreatic islet cell therapy for type 1 diabetes (T1D). Patient enrollment for a Phase 1/2 clinical trial is planned

Sernova and Seraxis close $11.2M financing ahead of merger

Mon, 05 Oct 2026 07:00:42 -0400

Participants in the financing include company insiders, management from both Sernova and Seraxis, existing shareholders, and new investors.

Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial

Mon, 05 Oct 2026 07:00:00 -0400

TORONTO and GERMANTOWN, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO) and Seraxis Holdings, Inc. (“Seraxis”) today announced the closing of the previously announced targeted US$10 million non-brokered convertible note financing in connection with their proposed merger (the "Merger") to form BetaNova Biotherapeutics, Inc. (“BetaNova”).

The US$11.2 million financing into Seraxis includes participation from insiders, Dr. Steven Sangha / Arlo Investments, Sernova management; Jonathan Rigby CEO, James Parsons CFO, Marylyn Rigby CCO, and David Burke VP IR, as well as Seraxis management; Will Rust Ph.D. CEO,

Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial

Mon, 05 Oct 2026 07:00:00 -0400

Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial

Mon, 05 Oct 2026 07:00:00 -0400

Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial

Mon, 05 Oct 2026 07:00:00 -0400

Sernova Biotherapeutics to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference

Fri, 25 Sep 2026 07:00:00 -0400

TORONTO and GERMANTOWN, Md., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics (“Sernova”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a clinical-stage regenerative medicine company focused on developing cell therapies with the goal of delivering a functional cure for type 1 diabetes (T1D), today announced Sernova and Seraxis Holdings, Inc. (“Seraxis”) will participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference on Thursday, October 1, at 1:30 p.m. Eastern Time.

Jonathan Rigby, President and CEO of Sernova, will be joined by Will Rust, Ph.D., President and CEO of Seraxis, for a joint presentation and fireside-style

Sernova Biotherapeutics to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference

Fri, 25 Sep 2026 07:00:00 -0400

Jonathan Rigby, President and CEO of Sernova, will be joined by Will Rust, Ph.D., President and CEO of Seraxis, for a joint presentation and fireside-style

Sernova Biotherapeutics to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference

Fri, 25 Sep 2026 07:00:00 -0400

Jonathan Rigby, President and CEO of Sernova, will be joined by Will Rust, Ph.D., President and CEO of Seraxis, for a joint presentation and fireside-style

Sernova Biotherapeutics to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference

Fri, 25 Sep 2026 07:00:00 -0400

Jonathan Rigby, President and CEO of Sernova, will be joined by Will Rust, Ph.D., President and CEO of Seraxis, for a joint presentation and fireside-style

Sernova Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investor Conference

Thu, 10 Sep 2026 07:00:00 -0400

TORONTO and GERMANTOWN, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics (“Sernova”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes, today announced it will be participating in the upcoming H.C. Wainwright 28th Annual Global Investment Conference being held September 14-16, 2026, in New York. Jonathan Rigby, Sernova’s President and CEO, will be joined by Will Rust, Ph.D., President and CEO of Seraxis Holdings, Inc. ("Seraxis") and a joint, in-person presentation will be made on Wednesday 16th September

Sernova Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investor Conference

Thu, 10 Sep 2026 07:00:00 -0400

Sernova Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investor Conference

Thu, 10 Sep 2026 07:00:00 -0400

Sernova Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investor Conference

Thu, 10 Sep 2026 07:00:00 -0400

Sernova and Seraxis agree to merge, forming BetaNova Biosciences

Tue, 08 Sep 2026 07:01:41 -0400

Sernova Biotherapeutics Inc. (TSX: SVA) (OTC: SEOVF) and Seraxis Holdings, Inc. have entered into a definitive agreement to merge and form a new company called BetaNova Biotherapeutics, Inc., focused on type 1 diabetes (T1D) islet cell replacement therapy.

Under the terms of the agreement, shareholders of both Sernova and Seraxis will each own approximately 50% of BetaNova upon completion of the merger. The combined company will be headquartered in Germantown, Maryland, and will incorporate Sernova's Cell Pouch Bio-hybrid Organ with Seraxis' stem cell-derived pancreatic islet cells and in-house cGMP manufacturing capabilities.

A $10 million non-brokered convertible note financing has been secured from

Sernova and Seraxis agree to merge, forming BetaNova Biosciences

Tue, 08 Sep 2026 07:01:41 -0400

A $10 million non-brokered convertible note financing has been secured from

Sernova and Seraxis Enter Definitive Merger Agreement to Create a Differentiated Type 1 Diabetes Islet Cell-Replacement Biotech Company, BetaNova Biotherapeutics

Tue, 08 Sep 2026 07:00:00 -0400

Merger unites Sernova's Cell Pouch Bio-hybrid Organ with Seraxis' stem cell-derived pancreatic islet cells and in-house cGMP manufacturing
The combined entity will operate under the name BetaNova Biotherapeutics, Inc.
SR-02 allogeneic islet cell therapy Phase 1/2 clinical trial in T1D expected to dose patients Q1 2027 under an FDA-cleared IND (NCT07581197) with data anticipated by mid-year
SR-03 next-generation gene-edited islet cell therapy targeting immune evasion; IND submission expected H2 2027
US$10 million non-brokered financing secured to fund initial development plans to key milestones
Merger expected to close in November 2026, subject to

Sernova and Seraxis Enter Definitive Merger Agreement to Create a Differentiated Type 1 Diabetes Islet Cell-Replacement Biotech Company, BetaNova Biotherapeutics

Tue, 08 Sep 2026 07:00:00 -0400

Merger unites Sernova's Cell Pouch Bio-hybrid Organ with Seraxis' stem cell-derived pancreatic islet cells and in-house cGMP manufacturing
The combined entity will operate under the name BetaNova Biotherapeutics, Inc.
SR-02 allogeneic islet cell therapy Phase 1/2 clinical trial in T1D expected to dose patients Q1 2027 under an FDA-cleared IND (NCT07581197) with data anticipated by mid-year
SR-03 next-generation gene-edited islet cell therapy targeting immune evasion; IND submission expected H2 2027
US$10 million non-brokered financing secured to fund initial development plans to key milestones
Merger expected to close in November 2026, subject to

Form 6-K SINOVAC BIOTECH LTD For: Aug 17

Mon, 17 Aug 2026 08:12:00 -0400

si-local-file:///var/storage/secattach/20260817/26935201.html

Form 6-K SINOVAC BIOTECH LTD For: Aug 17

Mon, 17 Aug 2026 08:12:00 -0400

si-local-file:///var/storage/secattach/20260817/26935201.html

SINOVAC Reports Unaudited First Half of 2026 Financial Results

Mon, 17 Aug 2026 08:00:00 -0400

BEIJING--(BUSINESS WIRE)-- Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it filed its unaudited financial results for the six months ended June 30, 2026 with the U.S. Securities and Exchange Commission. An electronic copy of the financial results can be accessed at the Company’s website at www.sinovac.com and at the SEC’s website www.sec.gov.